Korea Exchange · Healthcare
GC Biopharma stock from India: price, numbers and tax
GC Biopharma (006280) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
GC Biopharma at a glance
- Price
- ₩129,400.00-₩1,100.00 (0.84%)
- Market cap
- ₩1.48T
- Day range
- ₩127,900.00 – ₩130,500.00
- P/E
- -29.60
- Dividend yield
- 1.16%
- Volume
- 37.47K
- 1 month
- -0.54%
- 6 months
- -10.33%
- YTD
- -18.62%
- 1 year
- -0.61%
- 5 years
- -52.51%
GC Biopharma statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩2.0T | ₩1.7T | ₩1.6T | ₩1.7T | ₩1.5T |
| Gross profit | ₩536.0B | ₩481.9B | ₩484.6B | ₩581.8B | ₩520.6B |
| Operating income | ₩67.8B | ₩32.1B | ₩34.4B | ₩81.3B | ₩73.7B |
| Net income | −₩4.7B | −₩26.3B | −₩26.6B | ₩65.5B | ₩123.2B |
| Earnings per share | −₩409.51 | −₩2,302.62 | −₩2,333.42 | ₩5,734.87 | ₩10,795.00 |
| EBITDA | ₩155.5B | ₩80.4B | ₩109.8B | ₩187.3B | ₩159.4B |
| Total assets | ₩3.0T | ₩2.7T | ₩2.6T | ₩2.5T | ₩2.5T |
| Total debt | ₩982.1B | ₩828.1B | ₩724.0B | ₩575.5B | ₩606.6B |
| Cash and short-term investments | ₩50.8B | ₩24.0B | ₩55.5B | ₩112.3B | ₩202.9B |
| Shareholders' equity | ₩1.2T | ₩1.3T | ₩1.3T | ₩1.3T | ₩1.3T |
| Operating cash flow | ₩99.5B | −₩53.5B | −₩5.5B | ₩119.2B | ₩126.0B |
| Free cash flow | ₩27.1B | −₩95.9B | −₩131.5B | ₩24.5B | ₩2.4B |
| Capital expenditure | −₩72.4B | −₩42.4B | −₩126.0B | −₩94.7B | −₩123.5B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Hanmi Pharm. | 128940.KS | ₩480,500.00 | ₩6.09T |
| Yuhan | 000100.KS | ₩73,100.00 | ₩5.38T |
| Hanall Biopharma | 009420.KS | ₩44,000.00 | ₩2.24T |
| Celltrion Pharm | 068760.KQ | ₩38,800.00 | ₩1.72T |
| Daewoong pharmaceutical | 069620.KS | ₩108,500.00 | ₩1.25T |
| Chong Kun Dang Pharmaceutical | 185750.KS | ₩65,900.00 | ₩868.30B |
| Dong-A Socio | 000640.KS | ₩93,000.00 | ₩626.13B |
| JW Pharmaceutical | 001060.KS | ₩26,350.00 | ₩608.52B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in GC Biopharma from India
What GC Biopharma does
GC Biopharma Corp. is a pharmaceutical enterprise primarily involved in the production and distribution of various medical products. Its extensive portfolio encompasses specialized treatments for blood-related conditions, non-prescription remedies, general medications, and immunizations, among other therapeutic solutions. GC Biopharma operates in the Medical - Pharmaceuticals industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell GC Biopharma shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.